Heidi Roschitzki‐Voser

A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial

Sanjay Popat, Alessandra Curioni‐Fontecedro, Urania Dafni et al. · Annals of Oncology · 2020 · 273 citations · Full text

Medicine, Oncology, Pharmacology +16

Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer—The ETOP NICOLAS trial

Solange Peters, Enriqueta Felip, Urania Dafni et al. · Lung Cancer · 2019 · 161 citations

Medicine, Oncology, Pharmacotherapy +16

Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP)

Rafał Dziadziuszko, Egbert F. Smit, Urania Dafni et al. · Journal of Thoracic Oncology · 2019 · 155 citations · Full text

Medicine, Oncology, Pharmacology +17

Progression-Free and Overall Survival for Concurrent Nivolumab With Standard Concurrent Chemoradiotherapy in Locally Advanced Stage IIIA-B NSCLC: Results From the European Thoracic Oncology Platform NICOLAS Phase II Trial (European Thoracic Oncology Platform 6-14)

Solange Peters, Enriqueta Felip, Urania Dafni et al. · Journal of Thoracic Oncology · 2020 · 136 citations · Full text

Medicine, Oncology, Chemotherapy +15

Inhibition of Caspase-2 by a Designed Ankyrin Repeat Protein: Specificity, Structure, and Inhibition Mechanism

Andreas Schweizer, Heidi Roschitzki‐Voser, Patrick Amstutz et al. · Structure · 2007 · 130 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +12